Generic Drug Development CDMO

Introduction Evaluating a peptide purity testing report requires a systematic review of analytical parameters to distinguish raw chromatographic purity from […]

Introduction Rescuing a delayed Phase I program depends on replacing fragmented, multi-vendor outsourcing arrangements with a single, integrated Contract Development

Introduction An ICH Q3D Elemental Impurity Assessment provides a systematic, science-based safety framework for identifying, quantifying, and controlling toxic elemental

Introduction Building an IND-Enabling CMC Analytical Package for a virtual biotech requires establishing a phase-appropriate, regulatory-compliant analytical data package that

Introduction When a drug product is transferred to a new contract facility, executing an Analytical Method Transfer and Re-Validation ensures

Introduction Engaging specialized GMP Release and Stability Testing Services at a CDMO enables biopharmaceutical developers to access validated analytical testing,

1. Introduction Solid-state characterization and polymorph screening are essential components of pharmaceutical development because the physical form of an active

Introduction: Oligonucleotide CDMO Services give drug developers a single, analytically grounded route from sequence design to GMP drug substance, and

Introduction: ICH Q3D elemental impurities risk assessment is a critical part of pharmaceutical quality management, because metals can enter drug

Introduction Selecting between an integrated contract development and manufacturing organization (CDMO) and multiple specialized vendors depends on whether a drug